These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10091618)

  • 41. Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease.
    Ondarza R; Velasco F; Velasco M; Aceves J; Flores G
    Stereotact Funct Neurosurg; 1994; 62(1-4):90-7. PubMed ID: 7631094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant therapy of parkinsonian tremor.
    Koller WC; Herbster G
    Arch Neurol; 1987 Sep; 44(9):921-3. PubMed ID: 3619710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postural tremor of Parkinson's disease.
    Henderson JM; Yiannikas C; Morris JG; Einstein R; Jackson D; Byth K
    Clin Neuropharmacol; 1994 Jun; 17(3):277-85. PubMed ID: 9316673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Linear and nonlinear tremor acceleration characteristics in patients with Parkinson's disease.
    Meigal AY; Rissanen SM; Tarvainen MP; Georgiadis SD; Karjalainen PA; Airaksinen O; Kankaanpää M
    Physiol Meas; 2012 Mar; 33(3):395-412. PubMed ID: 22370008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients.
    Winogrodzka A; Wagenaar RC; Bergmans P; Vellinga A; Booij J; van Royen EA; van Emmerik RE; Stoof JC; Wolters EC
    Mov Disord; 2001 Nov; 16(6):1033-40. PubMed ID: 11748734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Latency of re-emergent tremor in Parkinson's disease is influenced by levodopa.
    Wilken M; Rossi MD; Rivero AD; Hallett M; Merello M
    Parkinsonism Relat Disord; 2019 Apr; 61():166-169. PubMed ID: 30348494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinson's disease.
    Wu J; Zhou C; Guo T; Guan X; Gao T; Bai X; Wu H; Chen J; Wen J; Liu X; Gu L; Song Z; Xuan M; Gu Q; Huang P; Pu J; Zhang B; Xu X; Zhang M
    Brain Imaging Behav; 2022 Jun; 16(3):1234-1245. PubMed ID: 34973120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
    Tarsy D; Scollins L; Corapi K; O'Herron S; Apetauerova D; Norregaard T
    Stereotact Funct Neurosurg; 2005; 83(5-6):222-7. PubMed ID: 16534254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Budipine in Parkinson's tremor.
    Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):53-5. PubMed ID: 16784759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.
    Friedman JH; Koller WC; Lannon MC; Busenbark K; Swanson-Hyland E; Smith D
    Neurology; 1997 Apr; 48(4):1077-81. PubMed ID: 9109903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of resting tremor by beta-adrenergic blockade.
    Foster NL; Newman RP; LeWitt PA; Gillespie MM; Chase TN
    Am Heart J; 1984 Oct; 108(4 Pt 2):1173-7. PubMed ID: 6148881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tremors in early Parkinson's disease.
    Koller WC; Vetere-Overfield B; Barter R
    Clin Neuropharmacol; 1989 Aug; 12(4):293-7. PubMed ID: 2804993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tremor-predominant Parkinson's disease. Approaches to treatment.
    Marjama-Lyons J; Koller W
    Drugs Aging; 2000 Apr; 16(4):273-8. PubMed ID: 10874522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical treatment of essential tremor and Parkinson's disease.
    Uitti RJ
    Geriatrics; 1998 May; 53(5):46-8, 53-7. PubMed ID: 9597979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease.
    Kompoliti K; Wang QE; Goetz CG; Leurgans S; Raman R
    Neurology; 2000 Jan; 54(2):458-62. PubMed ID: 10668714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [L-dopa, biperiden and sebum excretion in Parkinson disease].
    Villares JC
    Arq Neuropsiquiatr; 1989 Mar; 47(1):31-8. PubMed ID: 2764750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.
    Bhidayasiri R; Sringean J; Anan C; Boonpang K; Thanawattano C; Ray Chaudhuri K
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S36-S41. PubMed ID: 27939326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy.
    Binder S; Deuschl G; Volkmann J
    Eur Neurol; 2009; 61(3):149-53. PubMed ID: 19092251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.